1. Home
  2. DGII vs ZYME Comparison

DGII vs ZYME Comparison

Compare DGII & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digi International Inc.

DGII

Digi International Inc.

HOLD

Current Price

$47.78

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$22.62

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DGII
ZYME
Founded
1985
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
DGII
ZYME
Price
$47.78
$22.62
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
9
Target Price
$48.80
$32.75
AVG Volume (30 Days)
336.4K
594.4K
Earning Date
02-04-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
17.55
N/A
EPS
1.12
N/A
Revenue
$448,817,000.00
$134,481,000.00
Revenue This Year
$12.80
$63.10
Revenue Next Year
$5.47
$93.26
P/E Ratio
$43.08
N/A
Revenue Growth
6.40
116.21
52 Week Low
$22.39
$9.03
52 Week High
$48.33
$28.49

Technical Indicators

Market Signals
Indicator
DGII
ZYME
Relative Strength Index (RSI) 65.02 43.91
Support Level $44.88 $22.07
Resistance Level $47.73 $22.93
Average True Range (ATR) 2.41 0.86
MACD 0.31 0.06
Stochastic Oscillator 99.26 34.62

Price Performance

Historical Comparison
DGII
ZYME

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: